Company Encyclopedia
View More
name
BCHT
688276.SH
Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. The company’s products include herpes zoster vaccine; varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and rabies vaccine (vero cell) for humans. Changchun BCHT Biotechnology Co.
1.568 T
688276.SHMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking69/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.18%D
    • Profit Margin-25.17%E
    • Gross Margin74.10%A
  • Growth ScoreE
    • Revenue YoY-57.85%E
    • Net Profit YoY-141.16%E
    • Total Assets YoY-1.95%D
    • Net Assets YoY-5.77%D
  • Cash ScoreE
    • Cash Flow Margin-397.31%D
    • OCF YoY-57.85%E
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreB
    • Gearing Ratio24.04%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BCHT Biotechnology Gets Nod to Trial Vaccines Against Pertussis, Diphtheria, Tetanus

    BCHT Biotechnology Gets Nod to Trial Vaccines Against Pertussis, Diphtheria, Tetanus

    marketscreener·
    SH
    688276
    -5.81%
    marketscreener·
    SH
    688276
    -5.81%

    Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Changchun BCHT Biotechnology Co. reported a significant decline in earnings for the nine months ended September 30, 2025. Sales dropped to CNY 474.44 million from CNY 1,026.01 million the previous year. The company faced a net loss of CNY 158.25 million, contrasting with a net income of CNY 244.37 million in the same period last year. Basic and diluted loss per share from continuing operations were both CNY 0.38, down from earnings of CNY 0.59 per share a year ago.

    marketscreener·
    SH
    688276
    -5.81%
    marketscreener·
    SH
    688276
    -5.81%

    Changchun High-tech's subsidiary's clinical trial application for the trivalent influenza virus split vaccine (BK-01 adjuvant) has been approved

    According to the Zhitong Finance APP, Changchun Gaoxin announced that its subsidiary BCHT received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant), agreeing to conduct clinical trials for the prevention of influenza caused by related types of influenza viruses

    Zhitong·
    SH
    688276
    -5.81%
    Zhitong·
    SH
    688276
    -5.81%

    BCHT: Approval granted for clinical trial application of acellular DTP b-type influenza Haemophilus influenzae combined vaccine

    BCHT recently received approval from the National Medical Products Administration to conduct clinical trials for the acellular pertussis-diphtheria-tetanus combined vaccine against Haemophilus influenzae type b. This vaccine can prevent whooping cough, diphtheria, tetanus, and infections caused by Haemophilus influenzae type b, and is suitable for infants aged 2 months and older. If the clinical trials are successful and approved for market launch, it will help the company optimize its product structure, promote the development of its main business, and provide the public with higher quality vaccine options

    Zhitong·
    SH
    688276
    -5.81%
    Zhitong·
    SH
    688276
    -5.81%

    BCHT has launched Phase I clinical trials for the HSV-2 mRNA vaccine

    BCHT held the launch meeting for the Phase I clinical trial of the HSV-2 mRNA vaccine on September 9th at the Beijing Jishuitan Hospital. The meeting covered topics including the background of genital herpes disease and vaccine development, GCP standards, and the clinical trial protocol. All preparations are complete, and the subject enrollment work is about to commence in full

    Zhitong·
    SH
    688276
    -5.81%
    Zhitong·
    SH
    688276
    -5.81%